Mounjaro, also known as tirzepatide, received its initial U.S. Food and Drug Administration (FDA) approval on May 13, 2022 [1]. This approval was for the treatment of adults with type 2 diabetes [1].
What other conditions might Mounjaro be used for?
Tirzepatide is also being investigated for other health conditions. Clinical trials have explored its effectiveness in weight management, and in February 2024, the FDA approved tirzepatide for chronic weight management in adults with obesity or who are overweight and have at least one weight-related condition [2]. Further research is ongoing for conditions like heart failure [3].
When did Mounjaro become available for patients?
Following its FDA approval in May 2022, Mounjaro became available to patients shortly thereafter. The drug is manufactured by Eli Lilly and Company [1].
What is the mechanism of action for Mounjaro?
Mounjaro is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [4]. It works by mimicking the actions of these natural hormones to help regulate blood sugar and appetite [4]. By stimulating insulin secretion, reducing glucagon secretion, slowing gastric emptying, and affecting satiety, tirzepatide helps lower blood glucose levels and can lead to weight loss [4].
How does Mounjaro compare to other diabetes medications?
Mounjaro represents a different approach compared to many other diabetes medications. For instance, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) primarily target the GLP-1 pathway. Mounjaro's dual GIP and GLP-1 action is intended to offer potentially enhanced efficacy in glycemic control and weight reduction [4]. Studies have shown tirzepatide to be more effective than semaglutide in reducing HbA1c levels and body weight in individuals with type 2 diabetes [5].
What is the patent status for Mounjaro?
Drug patents provide market exclusivity for a period. Information regarding specific patent expiry dates for tirzepatide and its formulations can be found through specialized patent tracking resources [6]. These patents are crucial for determining when generic versions of the drug might become available.
What are the expected side effects of Mounjaro?
Common side effects reported with Mounjaro include nausea, vomiting, diarrhea, decreased appetite, constipation, indigestion, and abdominal pain [1]. More serious, though less common, side effects can include pancreatitis, gallbladder problems, kidney problems, serious allergic reactions, and thyroid tumors [1].
What is the cost of Mounjaro?
The price of Mounjaro can vary based on insurance coverage, pharmacy, and dosage. As of its launch, the list price was around $1,023 per month for the medication [7]. Patient assistance programs and co-pay coupons may be available to help reduce out-of-pocket costs [7].
Are there any regulatory hurdles or ongoing studies for Mounjaro?
Mounjaro's journey has involved extensive clinical trials to support its approvals for type 2 diabetes and weight management [2][3]. Ongoing research continues to explore its potential benefits and safety profile in various patient populations and for additional indications. Regulatory agencies worldwide review this data to make approval decisions.
---
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214852
[2] https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa2302090
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885053/
[5] https://www.nejm.org/doi/full/10.1056/NEJMoa2204331
[6] https://drugpatentwatch.com/
[7] https://www.goodrx.com/mounjaro